Oncotelic Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $249.3M | $-4.5M | $-7.9M | $5.1M | $-9.4M | $-9.5M | $-6.6M | $-712.7K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | $10.1K | $37.4K | $9.2K | $2.0K |
| Amortization | — | — | — | $12.8K | $51.4K | $326.8K | $51.4K | $34.2K |
| Stock-Based Compensation | $2.4M | — | — | $902.1K | $763.3K | $2.1M | $340.7K | $80.0K |
| Net Cash from Operating Activities | $-1.4M | $-740.3K | $-1.3M | $-1.5M | $-4.4M | $-2.8M | $-2.3M | $-241.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | $189.3K | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.4M | $656.0K | $1.3M | $1.1M | $4.5M | $3.2M | $2.2M | $240.0K |
| Net Change in Cash | $2.7K | $-84.3K | $-71.0K | $-327.3K | $94.8K | $412.1K | $79.5K | $-486.0K |
| Free Cash Flow | — | — | — | — | — | — | — | — |